ProCE Banner Activity

Switching ART Without a “STIFF Cost”: Individualizing ART in Patients Who Are Virologically Suppressed

Clinical Thought

Just because a person is virologically suppressed on their ART regimen, doesn't mean you can’t switch it. Here’s why I think you should consider individualizing ART more often in your patients.

 

Released: June 28, 2023

Share

Faculty

Roger Bedimo

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas

Provided by

Provided by Clinical Care Options LLC

ProCE Banner

Supporters

This activity is supported through an Independent Medical Education grant from Merck Sharp & Dohme LLC, Rahway, NJ, USA.

Merck Sharp & Dohme LLC, Rahway, NJ, USA

Disclosure

Primary Author

Roger Bedimo, MD, MS, FACP

Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo, MD, MS, FACP: consultant/advisor/speaker: Gilead, Janssen, Merck & Co., Theratechnologies, ViiV; researcher: Merck & Co., Shionogi.